What are your top takeaways in Head & Neck Cancers from ASCO 2022?

In nasopharyngeal cancer, the group from Sun Yat-Sen University presented the results of a non-inferiority, randomized phase III study comparing RT alone vs RT concurrent with cisplatin for intermediate-risk patients (stage II and T3N0M0) (Ma et al., 2022 ASCO Annual Meeting, abstract #6000). They f...

Tata Memorial Docetaxel Trial (6003)

Takeaway: Docetaxel improved DFS and OS compared to RT alone in cisplatin-ineligible patients.

Details:

• 356 cisplatin-ineligible patients with locally advanced disease needing definitive or adjuvant CRT.
• Randomized to concurrent docetaxel 15 mg/m2 weekly for a ...